Search clinical trials for: Sustained Virologic Response 12 weeks post dosing (SVR12)

Total 72651 results

Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Chronic Hepatitis C
National Cancer Institute (NCI)

Active, not recruiting

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small Cell Carcinoma

United States
Australian National University

Recruiting

Nebulised Heparin in Patients With Severe COVID-19 (CHARTER-MT)

Covid19 | Respiratory Failure

United States
Austrian Breast & Colorectal Cancer Study Group
AstraZeneca; Novartis Pharmaceuticals

Completed

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

Breast Cancer

Austria, Germany
Cheerain HK Limited

Completed

Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by Smokers

Electronic Cigarette Use

United States
AOP Orphan Pharmaceuticals AG

Not yet recruiting

Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

Pulmonary Arterial Hypertension

Spain, Austria, France, Hungary
SEAMEO Regional Centre for Food and Nutrition
University of Otago; USDA, Western Human Nutrition Research Center; Universitas... and other collaborators

Active, not recruiting

Sustainable Intervention of Supplementation to Improve Kid's Growth Study (SISTIK-G)

Micronutrients | Birth Length | Linear Growth | Dietary Intakes

Indonesia
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Melanoma | Skin Cancer

United States
AbbVie

Completed

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, France, Germany, Poland, Puerto Rico, Russian Federation, Spain, United Kingdom
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
UCB Pharma SA
ReSearch Pharmaceutical Services, Inc.

Completed

Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol (SONAR-12)

Rheumatoid Arthritis

Spain
University of Zurich

Completed

Zurich Disability Prevention Trial (ZDPT)

Community-dwelling Seniors | History of a Fall in the Previous 12 Months

Switzerland
UCB BIOSCIENCES GmbH
PPD

Completed

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Crohn Disease

Russian Federation, Belgium, United States, Australia, Austria, Brazil, Canada, Czechia, Estonia, Germany, Hungary, Israel, Italy, Latvia, New Zealand, Poland, Romania, Ukraine
UCB Italy s.p.a.

Completed

Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (SPEED)

Rheumatoid Arthritis

Italy
UCB Pharma

Completed

Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients (RA-PROACTIVE)

Arthritis,Rheumatoid

Ireland, United Kingdom
All India Institute of Medical Sciences, Rishikesh

Unknown

Postoperative Analgesic Effects of Infraorbital Nerve Block in Cleft Palate Surgery

Pain, Postoperative

India
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

HCV

China
xuna

Recruiting

A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML

MMR on 12 Month

China
UCB Pharma

Terminated

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide (VICTOR)

Epilepsy, Partial

Austria, Germany, Spain
UCB Pharma SA

Completed

Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures

Epilepsy | Partial Seizures

China
UCB Biopharma S.P.R.L.
PRA Health Sciences

Completed

Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease (NEUPART)

Idiopathic Parkinson's Disease

Germany, France, Italy, Spain, United Kingdom
UCB Korea Co., Ltd.

Completed

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Idiopathic Parkinson's Disease

Korea, Republic of
UCB Pharma GmbH

Completed

Observation of Treatment With Certolizumab Pegol in Daily Practice (FasT)

Rheumatoid Arthritis

Germany
Korea UCB Co., Ltd.

Completed

Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy (OPTIMAL)

Epilepsy

Korea, Republic of
Sanol GmbH

Completed

A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects

Iron Deficiency Anemia

China
UCB Pharma

Completed

Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support (CARE-ACT)

Idiopathic Parkinson's Disease

Germany
UCB Pharma GmbH

Completed

Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch (NON-GI)

Idiopathic Parkinson's Disease

Germany
Chulalongkorn University
Ratchadapiseksompotch Research Fund

Completed

Pharmacokinetic of Everolimus and Atorvastatin Co-administration

Difference of 12-hour AUC

Thailand
Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland
Pierre Fabre Pharma AG

Completed

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). (Real-CHOICE)

Iron-Deficiency Anemia | Iron-Deficiency

Switzerland
InDex Pharmaceuticals

Completed

The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis (CONDUCT)

Ulcerative Colitis

Hungary, Czechia, France, Germany, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

Japan
UCB Japan Co. Ltd.

Completed

A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)

Epilepsy | Generalized Tonic-Clonic Seizures

China, Japan
UCB Pharma GmbH

Completed

Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease (NEUPAD)

Idiopathic Parkinson's Disease

Germany, Austria
UCB Korea Co., Ltd.

Completed

Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures

Epilepsy

Korea, Republic of
UCB Japan Co. Ltd.

Completed

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

Epilepsy | Partial Onset Seizures

Japan
UCB Pharma GmbH

Completed

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug (VITOBA)

Epilepsies, Partial

Germany
UCB Pharma

Completed

Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Japan
Nanfang Hospital of Southern Medical University

Recruiting

Withdrawal or Reduction TKIs in CML-CP

MMR on 12 Month

China
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
UCB Pharma

Completed

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Argentina, Australia, Belgium, Bulgaria, Canada, Chile, Croatia, Czechia, Estonia, Finland, France, Hungary, Israel, Latvia, Lithuania, Mexico, New Zealand, Russian Federation, Serbia, Slovakia, Ukraine
UCB Pharma SA
Parexel

Completed

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Rheumatoid Arthritis

Romania, United States, Australia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Mexico, Monaco, Poland, Portugal, Spain, Switzerland, United Kingdom
UCB Pharma

Completed

Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation (AURORA)

Restless Legs Syndrome

Germany
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
UCB Pharma

Completed

Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription

Narcolepsy

Austria, Belgium, Czech Republic, Germany, Ireland, Italy, Spain, Switzerland, United Kingdom
UCB Pharma

Terminated

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Rheumatoid Arthritis | Crohn's Disease

Russian Federation
UCB Japan Co. Ltd.

Completed

An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures

Epilepsy | Partial Seizures

Japan
University of Maryland, Baltimore
Rothman Institute Orthopaedics

Not yet recruiting

Is Physical Therapy Clearance Before Arthroplasty Home Discharge Necessary? (PTClearSHoT)

Physical Therapy | Total Joint Arthroplasty | Same-day Discharge

3

Subscribe